Burzynski Research Institute (BZYR) Cash & Equivalents (2010 - 2025)
Burzynski Research Institute (BZYR) posted Cash & Equivalents of $2165.0 for Q4 2025, up 132.55% sequentially from $931.0 in Q3 2025, and up 253.18% YoY from $613.0 in Q4 2024.
Burzynski Research Institute (BZYR) Cash & Equivalents (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Cash & Equivalents for 16 years, with the latest figure at $2165.0 in Q4 2025.
- Quarterly Cash & Equivalents rose 253.18% year-over-year to $2165.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $2165.0 (up 253.18% YoY) and the FY2025 annual result came in at $847.0, down 35.34% from the prior year.
- Cash & Equivalents advanced to $2165.0 in Q4 2025 per BZYR's latest filing, from $931.0 in the prior quarter.
- Over five years, Cash & Equivalents peaked at $5765.0 in Q4 2021 and troughed at $62.0 in Q1 2021.
- A 5-year average of $1501.2 and a median of $932.5 in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 5354.84% in 2022, then tumbled 96.89% in 2023.
- Over 5 years, Cash & Equivalents stood at $5765.0 in 2021, then plunged by 70.65% to $1692.0 in 2022, then slumped by 46.04% to $913.0 in 2023, then sank by 32.86% to $613.0 in 2024, then surged by 253.18% to $2165.0 in 2025.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $2165.0, $931.0, and $821.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 2,165.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 2,165.00 |
| Aug 31, 2025 | 931.00 |
| May 31, 2025 | 821.00 |
| Feb 28, 2025 | 847.00 |
| Nov 30, 2024 | 613.00 |
| Aug 31, 2024 | 1,216.00 |
| May 31, 2024 | 297.00 |
| Feb 29, 2024 | 1,310.00 |
| Nov 30, 2023 | 913.00 |
| Aug 31, 2023 | 1,397.00 |
| May 31, 2023 | 148.00 |
| Feb 28, 2023 | 934.00 |
| Nov 30, 2022 | 1,692.00 |
| Aug 31, 2022 | 1,266.00 |
| May 31, 2022 | 4,766.00 |
| Feb 28, 2022 | 3,382.00 |
| Nov 30, 2021 | 5,765.00 |
| Aug 31, 2021 | 904.00 |
| May 31, 2021 | 594.00 |
| Feb 28, 2021 | 62.00 |